Research Progress and Future Prospects of Three Oncolytic Viruses in the Treatment of Melanoma

Lizhou Fang

doi:10.62051/bczpdj54

Authors

Lizhou Fang

DOI:

https://doi.org/10.62051/bczpdj54

Keywords:

Melanoma; Oncolytic virus; Immune checkpoint inhibitor.

Abstract

Melanoma is one of the more common tumors among young people, and the number of deaths caused by melanoma is increasing year by year. How to find efficient and safe treatment methods is currently a problem that needs to be solved. At present, most melanoma patients are treated through surgical resection, but the recurrence rate is higher and the effect is poor. Research has found that oncolytic virus therapy alone or in combination with other methods (radiotherapy, cell therapy, immunotherapy) not only has a high acceptance rate for patients, but also has a lower recurrence rate due to better healing. The three viruses that are currently being studied extensively are herpes simplex virus, Coxsackie virus, and vesicular stomatitis virus. In the future, it may become a first-line treatment method. This article mainly discusses the current research progress and therapeutic effects of three viruses, as well as the research on their corresponding variants. Provide corresponding suggestions for future development direction.

Downloads

Download data is not yet available.

References

[1] Arnold M, Singh D, et al. Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. JAMA Dermatol. 2022 May 1; 158 (5): 495 - 503.

[2] Silk AW, O'Day SJ, et al. A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study. Cancer Immunol Immunotherapy. 2023 Jun; 72 (6): 1405 - 1415.

[3] Curti BD, Richards J, et al. Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study. J Immunother Cancer. 2022 Dec; 10 (12): e005224.

[4] Lutzky J, Sullivan RJ, et al. Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma. J Cancer Res Clin Oncol. 2023 Aug; 149 (9): 6059 - 6066.

[5] Chesney JA, Ribas A, et al. Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined with Pembrolizumab for Advanced Melanoma. J Clin Oncol. 2023 Jan 20; 41(3): 528 - 540.

[6] Chesney JA, Puzanov I, et al. Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial. J Immunother Cancer. 2023 May; 11 (5): e006270.

[7] Almutairi AR, Alkhatib NS, et al. Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients with Advanced Unresectable Melanoma. JAMA Dermatol. 2019 Jan 1; 155 (1): 22 - 28.

[8] Schwarze JK, Tijtgat J, et al. Intratumoral administration of CD1c (BDCA-1) + and CD141 (BDCA-3) + myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial. J Immunother Cancer. 2022 Sep; 10 (9): e005141.

[9] Cui C, Wang X, et al. OrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: a phase Ib study. J Immunother Cancer. 2022 Apr; 10 (4): e004307.

[10] Yamazaki N, Isei T, et al. A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma. Cancer Sci. 2022 Aug; 113 (8): 2798 - 2806.

[11] Ryapolova A, Minskaia E, et al. Development of Recombinant Oncolytic rVSV-mIL12-mGMCSF for Cancer Immunotherapy. Int J Mol Sci. 2023 Dec 22; 25 (1): 211.

[12] Smith KER, Peng KW, et al. A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses. Front Immunol. 2023 Oct 31; 14: 1279387.

[13] Webb MJ, Kottke T, et al. Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses. Mol Ther Oncolytics. 2023 May 22; 29: 129 - 142.

[14] Marek J, Hanesch L, et al. Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy. Mol Ther Oncolytics. 2023 Aug 5; 30: 117 - 131.

[15] Alkayyal AA, Ajina R, et al. SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus. Front Immunol. 2023 Jan 31; 14: 1082191.